Core Viewpoint - Garden Bio is focused on the development, production, and sales of generic drugs for chronic diseases, particularly in the cardiovascular and nervous system sectors, and has not yet ventured into innovative drugs [1] Company Overview - Garden Bio was established in December 2000 and was listed on the Shenzhen Stock Exchange's ChiNext board on October 9, 2014 [1] - The company has developed a complete industrial chain for Vitamin D3 over more than two decades [1] - Garden Bio's four main product categories—refined lanolin, lanosterol, Vitamin D3, and 25-hydroxy Vitamin D3—are among the global leaders in production capacity [1] Financial Performance - In the first half of 2025, Garden Bio reported revenue of approximately 635 million yuan, representing a year-on-year increase of 5.86% [1] - The net profit attributable to the parent company was approximately 162 million yuan, reflecting a year-on-year increase of 13.67% [1] Future Disclosure - The company has scheduled the disclosure date for its Q3 2025 report on October 18, 2025, and investors are encouraged to monitor the regular report for specific performance details [1]